Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Shan, Xiaoyin ^a   Margulies, Kenneth B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; PHOSPHODIESTERASE V; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CAT; CONTROLLED STUDY; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE HYPERTROPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; ANIMAL; AORTA; CYTOLOGY; DISEASE MODEL; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENE EXPRESSION REGULATION; HEART VENTRICLE; HUMAN; HYPERTROPHY; IMMUNOBLOTTING; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; SMOOTH MUSCLE;

EPINEPHELUS AMBLYCEPHALUS; FELIDAE;

AMINO ACID SEQUENCE; ANIMALS; AORTA; CATS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART VENTRICLES; HUMANS; HYPERTROPHY; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79956281314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019922     Document Type: Article

References (40)

1. Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, et al. (1998) Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43: 163-168.
2. Kass DA, Champion HC, Beavo JA, (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101: 1084-1095.
3. Biel M, Zong X, Ludwig A, Sautter A, Hofmann F, (1999) Structure and function of cyclic nucleotide-gated channels. Rev Physiol Biochem Pharmacol 135: 151-171.
4. Corbin JD, (2004) Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 16 (Suppl 1): S4-7.
5. Lin CS, (2004) Tissue expression, distribution, and regulation of PDE5. Int J Impot Res 16 (Suppl 1): S8-S10.
6. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, et al. (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172: 105-113.
7. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, et al. (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 39-45.
8. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, et al. (2004) A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 34-38.
9. Takimoto E, Champion HC, Li M, Belardi D, Ren S, et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222.
10. Hemnes AR, Zaiman A, Champion HC, (2008) PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 294: L24-33.
11. Das A, Xi L, Kukreja RC, (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280: 12944-12955.
12. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, et al. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238-248.
13. Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, et al. (2008) Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 10: 1158-1165.
14. Schafer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, et al. (2009) Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 82: 30-39.
15. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, et al. (2009) Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol 46: 560-567.
16. Kuhn M, (2009) Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent? Cardiovasc Res 82: 4-6.
17. Williams JF Jr, Potter RD, Hern DL, Mathew B, Deiss WP Jr, (1982) Hydroxyproline and passive stiffness of pressure-induced hypertrophied kitten myocardium. J Clin Invest 69: 309-314.
18. Bailey BA, Houser SR, (1992) Calcium transients in feline left ventricular myocytes with hypertrophy induced by slow progressive pressure overload. J Mol Cell Cardiol 24: 365-373.
19. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
20. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
21. Schultz J, Milpetz F, Bork P, Ponting CP, (1998) SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci U S A 95: 5857-5864.
22. Letunic I, Doerks T, Bork P, (2009) SMART 6: recent updates and new developments. Nucleic Acids Res 37: D229-232.
23. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, et al. (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119: 408-416.
24. Murata T, Shimizu K, Watanabe Y, Morita H, Sekida M, et al. (2010) Expression and role of phosphodiesterase 5 in human malignant melanoma cell line. Anticancer Res 30: 355-358.
25. Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, et al. (1996) Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal 8: 575-581.
26. Geng Y, Zhou L, Thompson WJ, Lotz M, (1998) Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes. J Biol Chem 273: 27484-27491.
27. Xu HL, Wolde HM, Gavrilyuk V, Baughman VL, Pelligrino DA, (2004) cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo. Am J Physiol Heart Circ Physiol 287: H2501-2509.
28. Lusche DF, Kaneko H, Malchow D, (2005) cGMP-phosphodiesterase antagonists inhibit Ca2+-influx in Dictyostelium discoideum and bovine cyclic-nucleotide-gated-channel. Eur J Pharmacol 513: 9-20.
29. Bessay EP, Blount MA, Zoraghi R, Beasley A, Grimes KA, et al. (2008) Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. J Pharmacol Exp Ther 325: 62-68.
30. Furukawa T, Kurokawa J, (2006) Potassium channel remodeling in cardiac hypertrophy. J Mol Cell Cardiol 41: 753-761.
31. Loiselle DS, Gibbs CL, (1979) Species differences in cardiac energetics. Am J Physiol 237: H90-98.
32. Moller G, Husen B, Kowalik D, Hirvela L, Plewczynski D, et al. Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1. PLoS One 5: e10969.
33. Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, et al. (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330: 884-891.
34. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, et al. (2001) Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. Faseb J 15: 1718-1726.
35. Takimoto E, Kass DA, (2009) Sildenafil's protective effect against cardiac hypertrophy. Expert Rev Clin Pharmacol 2: 323-327.
36. Olson EN, (2004) A decade of discoveries in cardiac biology. Nat Med 10: 467-474.
37. Ray JL, Leach R, Herbert JM, Benson M, (2001) Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci 23: 185-188.
38. Quaile MP, Rossman EI, Berretta RM, Bratinov G, Kubo H, et al. (2007) Reduced sarcoplasmic reticulum Ca(2+) load mediates impaired contractile reserve in right ventricular pressure overload. J Mol Cell Cardiol 43: 552-563.
39. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, et al. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57: 450-458.
40. Shan X, Wang H, Margulies KB, (2008) Apoptosis signal-regulating kinase 1 attenuates atrial natriuretic peptide secretion. Biochemistry 47: 10041-10048.